"In the years to come, Teva will seek to extend our global
leadership and deliver profitable growth, doubling our revenues by
2015 and reaching net income margins of 22%," said Shlomo Yanai,
Teva's President and CEO. "Our core business, generics, will
continue to drive our growth. At the same time, we will continue to
expand our branded business, further leveraging the diversity of
our balanced business model.”

The growing worldwide demand for generic pharmaceuticals –
as a means to expand access to affordable high-quality medicine and
control healthcare costs – will continue to drive the growth
of Teva's core business in the U.S. and globally. A significant
portion of this growth is expected to come from those European and
international markets that are currently characterized by low
generic penetration rates. Teva's branded business will be further
strengthened through internal R&D, licensing and other business
development opportunities, and geographic expansion of its existing
product portfolio – thereby enhancing its balanced business
model. Biogenerics is another important growth driver in Teva's
future. Teva remains committed to becoming a leading player in this
evolving market and has taken significant steps to build the
necessary infrastructure to accomplish this goal.

Teva's growth will be driven by its market leadership and
competitive advantages, including its scale and global footprint,
its high degree of back integration, the robustness of its product
portfolio and track record in being first to market in the U.S. and
other regions and its commitment to high quality. With these
competitive advantages, Teva will seek to outpace market
growth.

Mr. Yanai continued, "All of us at Teva are enthusiastic about
what we plan to achieve in the next five years, and in particular
about the value we expect to create for all of our
stakeholders."

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is
the world's leading generic pharmaceutical company and is among the
top 20 pharmaceutical companies in the world. The Company develops,
manufactures and markets generic and innovative human
pharmaceuticals and active pharmaceutical ingredients, as well as
animal health pharmaceutical products. Over 80 percent of Teva's
sales are in North America and Europe.

This release contains forward-looking statements, including,
among other things, regarding our expected profitable growth,
revenues, net income, the drivers and contributors of this growth,
strategy and competitive advantages, which express the current
beliefs and expectations of management. Such statements are based
on management's current beliefs and expectations and involve a
number of known and unknown risks and uncertainties that could
cause our future results, performance or achievements to differ
significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include
risks relating to: our ability to successfully develop and
commercialize additional pharmaceutical products, the introduction
of competing generic equivalents, the extent to which we may obtain
U.S. market exclusivity for certain of our new generic products and
regulatory changes that may prevent us from utilizing exclusivity
periods, potential liability for sales of generic products prior to
a final resolution of outstanding patent litigation, including that
relating to the generic versions of Neurontin®, Lotrel®,
Protonix® and Eloxatin®, the current economic conditions,
competition from brand-name companies that are under increased
pressure to counter generic products, or competitors that seek to
delay the introduction of generic products, the effects of
competition on our innovative products, especially Copaxone®
sales, including potential oral and generic competition for
Copaxone®, dependence on the effectiveness of our patents and
other protections for innovative products, the impact of
consolidation of our distributors and customers, the impact of
pharmaceutical industry regulation and pending legislation that
could affect the pharmaceutical industry, our ability to achieve
expected results though our innovative R&D efforts, the
difficulty of predicting U.S. Food and Drug Administration,
European Medicines Agency and other regulatory authority approvals,
the uncertainty surrounding the legislative and regulatory pathway
for the registration and approval of biotechnology-based products,
the regulatory environment and changes in the health policies and
structures of various countries, supply interruptions or delays
that could result from the complex manufacturing of our products
and our global supply chain, our ability to successfully identify,
consummate and integrate acquisitions, the potential exposure to
product liability claims to the extent not covered by insurance,
our exposure to fluctuations in currency, exchange and interest
rates, significant operations worldwide that may be adversely
affected by terrorism, political or economical instability or major
hostilities, our ability to enter into patent litigation
settlements and the intensified scrutiny by the U.S. government,
the termination or expiration of governmental programs and tax
benefits, impairment of intangible assets and goodwill,
environmental risks, and other factors that are discussed in this
report and in our other filings with the U.S. Securities and
Exchange Commission ("SEC").

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.